| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eb79af1032814c88fe9fffe658333123
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ffd80d1dbed443c2c7d825cc95cb2337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_23e9d15adaa197e78463456c56d94509
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2708a7ef15f863c94f5ffae357017be0 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C333-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C323-43
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-69
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D317-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C271-16 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C323-43
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C271-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C333-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D317-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-69 |
| filingDate |
1997-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2005-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ea9917962539ee8d1fb598b2ba40e45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1bd267e6dae6f102b0d28ddcf01eaeb6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b68203acc85b4aaab51b40babe250a77
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6d9389e9dd16b946e445a997aa0be82 |
| publicationDate |
2005-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0944583-B1 |
| titleOfInvention |
Novel compounds useful as therapeutic agents and assay reagents |
| abstract |
Novel pro-drugs and assay reagents are provided which are useful as therapeutic agents especially for delivery and targetting therapeutically active agents to melanoma cells. The pro-drugs and assay reagents are substrates for tyrosinase and may be represented by the formula TyrX-B-ThrAg*. The compounds of formula TyrX-B-ThrAg* are capable of releasing a therapeutically active agent or assayable substance (ThrAg) at a desired location. TyrX- being a residue of an optionally substituted tyrosine analogue. |
| priorityDate |
1996-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |